These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 38459626)
1. Stop codon readthrough as a treatment option for epidermolysis bullosa-Where we are and where we are going. Zandanell J; Wießner M; Bauer JW; Wagner RN Exp Dermatol; 2024 Mar; 33(3):e15042. PubMed ID: 38459626 [TBL] [Abstract][Full Text] [Related]
2. Emerging Personalized Opportunities for Enhancing Translational Readthrough in Rare Genetic Diseases and Beyond. Wagner RN; Wießner M; Friedrich A; Zandanell J; Breitenbach-Koller H; Bauer JW Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047074 [TBL] [Abstract][Full Text] [Related]
3. The minor gentamicin complex component, X2, is a potent premature stop codon readthrough molecule with therapeutic potential. Friesen WJ; Johnson B; Sierra J; Zhuo J; Vazirani P; Xue X; Tomizawa Y; Baiazitov R; Morrill C; Ren H; Babu S; Moon YC; Branstrom A; Mollin A; Hedrick J; Sheedy J; Elfring G; Weetall M; Colacino JM; Welch EM; Peltz SW PLoS One; 2018; 13(10):e0206158. PubMed ID: 30359426 [TBL] [Abstract][Full Text] [Related]
4. Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system. Keeling KM; Bedwell DM J Mol Med (Berl); 2002 Jun; 80(6):367-76. PubMed ID: 12072912 [TBL] [Abstract][Full Text] [Related]
5. Sequence specificity of aminoglycoside-induced stop condon readthrough: potential implications for treatment of Duchenne muscular dystrophy. Howard MT; Shirts BH; Petros LM; Flanigan KM; Gesteland RF; Atkins JF Ann Neurol; 2000 Aug; 48(2):164-9. PubMed ID: 10939566 [TBL] [Abstract][Full Text] [Related]
6. Aminoglycosides restore full-length type VII collagen by overcoming premature termination codons: therapeutic implications for dystrophic epidermolysis bullosa. Cogan J; Weinstein J; Wang X; Hou Y; Martin S; South AP; Woodley DT; Chen M Mol Ther; 2014 Oct; 22(10):1741-52. PubMed ID: 25155989 [TBL] [Abstract][Full Text] [Related]
7. Statistical analysis of readthrough levels for nonsense mutations in mammalian cells reveals a major determinant of response to gentamicin. Floquet C; Hatin I; Rousset JP; Bidou L PLoS Genet; 2012; 8(3):e1002608. PubMed ID: 22479203 [TBL] [Abstract][Full Text] [Related]
8. Serum starvation enhances nonsense mutation readthrough. Wittenstein A; Caspi M; David Y; Shorer Y; Nadar-Ponniah PT; Rosin-Arbesfeld R J Mol Med (Berl); 2019 Dec; 97(12):1695-1710. PubMed ID: 31786671 [TBL] [Abstract][Full Text] [Related]
9. Application of topical gentamicin-a new era in the treatment of genodermatosis. Wang S; Yang Z; Liu Y; Zhao MT; Zhao J; Zhang H; Liu ZY; Wang XL; Ma L; Yang YH World J Pediatr; 2021 Dec; 17(6):568-575. PubMed ID: 34787828 [TBL] [Abstract][Full Text] [Related]
10. Gentamicin induces Lincoln V; Cogan J; Hou Y; Hirsch M; Hao M; Alexeev V; De Luca M; De Rosa L; Bauer JW; Woodley DT; Chen M Proc Natl Acad Sci U S A; 2018 Jul; 115(28):E6536-E6545. PubMed ID: 29946029 [TBL] [Abstract][Full Text] [Related]
11. Gentamicin B1 is a minor gentamicin component with major nonsense mutation suppression activity. Baradaran-Heravi A; Niesser J; Balgi AD; Choi K; Zimmerman C; South AP; Anderson HJ; Strynadka NC; Bally MB; Roberge M Proc Natl Acad Sci U S A; 2017 Mar; 114(13):3479-3484. PubMed ID: 28289221 [TBL] [Abstract][Full Text] [Related]
12. Stop codon context influences genome-wide stimulation of termination codon readthrough by aminoglycosides. Wangen JR; Green R Elife; 2020 Jan; 9():. PubMed ID: 31971508 [TBL] [Abstract][Full Text] [Related]
13. Readthrough of dystrophin stop codon mutations induced by aminoglycosides. Howard MT; Anderson CB; Fass U; Khatri S; Gesteland RF; Atkins JF; Flanigan KM Ann Neurol; 2004 Mar; 55(3):422-6. PubMed ID: 14991821 [TBL] [Abstract][Full Text] [Related]
14. Gentamicin Induces Laminin 332 and Improves Wound Healing in Junctional Epidermolysis Bullosa Patients with Nonsense Mutations. Kwong A; Cogan J; Hou Y; Antaya R; Hao M; Kim G; Lincoln V; Chen Q; Woodley DT; Chen M Mol Ther; 2020 May; 28(5):1327-1338. PubMed ID: 32222156 [TBL] [Abstract][Full Text] [Related]
15. Pharmaceuticals Promoting Premature Termination Codon Readthrough: Progress in Development. Li S; Li J; Shi W; Nie Z; Zhang S; Ma F; Hu J; Chen J; Li P; Xie X Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371567 [TBL] [Abstract][Full Text] [Related]
16. Effect of small molecule eRF3 degraders on premature termination codon readthrough. Baradaran-Heravi A; Balgi AD; Hosseini-Farahabadi S; Choi K; Has C; Roberge M Nucleic Acids Res; 2021 Apr; 49(7):3692-3708. PubMed ID: 33764477 [TBL] [Abstract][Full Text] [Related]
17. [Therapeutic readthrough strategy for suppression of nonsense mutations in duchenne muscular dystrophy]. Shiozuka M; Matsuda R Brain Nerve; 2011 Nov; 63(11):1253-60. PubMed ID: 22068478 [TBL] [Abstract][Full Text] [Related]
18. Properties of Non-Aminoglycoside Compounds Used to Stimulate Translational Readthrough of PTC Mutations in Primary Ciliary Dyskinesia. Dabrowski M; Bukowy-Bieryllo Z; Jackson CL; Zietkiewicz E Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34066907 [TBL] [Abstract][Full Text] [Related]
19. Cancer syndromes and therapy by stop-codon readthrough. Bordeira-Carriço R; Pêgo AP; Santos M; Oliveira C Trends Mol Med; 2012 Nov; 18(11):667-78. PubMed ID: 23044248 [TBL] [Abstract][Full Text] [Related]
20. Intracellular readthrough of nonsense mutations by aminoglycosides in coagulation factor VII. Pinotti M; Rizzotto L; Pinton P; Ferraresi P; Chuansumrit A; Charoenkwan P; Marchetti G; Rizzuto R; Mariani G; Bernardi F; J Thromb Haemost; 2006 Jun; 4(6):1308-14. PubMed ID: 16706976 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]